search
Back to results

Interaction of Alcohol With Energy Drinks (AEDED)

Primary Purpose

Alcohol-Related Disorders, Drinking and Driving

Status
Completed
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
Alcohol and energy drink
Alcohol
Energy drink
Placebo
Sponsored by
Parc de Salut Mar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol-Related Disorders focused on measuring alcohol, energy drink, coagulability, caffeine, taurine, driving performance

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Understand and accept the study's procedures and sign an informed consent form
  • No evidence of somatic or psychiatric disorders as per past medical history and physical examination
  • EKG, blood and urine tests taken before entry into the study within the normal range. Minor and transient abnormalities may be acceptable if, according to the Principal Investigator's criterion and the state of the art, they are felt to have no clinical relevance, entail no danger to the participant, and don't interfere with the product's assessment. These abnormalities and their non-relevance must be specifically justified in writing)
  • Body mass index (BMI=weight/heigth2) between 19 and 27 kg/m2, weight between 50 and 100 kg
  • For premenopausal females, a regular menstrual cycle of 26-32 days duration.
  • Social or recreational alcohol consumption of at least 1 unit per day (or its equivalent [7 units] over the whole week) and having experienced drunkenness several times
  • Regular consumption of beverages containing methylxanthines (at least 5 per week)
  • Consumption of energy drinks several times previously
  • Having a driving license

Exclusion Criteria:

  • Evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of the drug or symptoms suggestive of drug-induced gastrointestinal irritation
  • Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs
  • Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  • Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial
  • Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks
  • Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session
  • Smokers of >5 cigarettes/day
  • Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  • Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study
  • Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals
  • Pregnant or lactating women, or those using hormonal or unreliable contraceptive methods during the study period. Complete abstinence, intrauterine devices, double barrier methods or a vasectomized sexual partner will be considered acceptable
  • Women with amenorrhea or suffering severe premenstrual syndrome
  • Individuals of Asian ascent

Sites / Locations

  • IMIM
  • Parc de Salut Mar-IMIM

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Alcohol and energy drink

Alcohol

Energy drink

Placebo

Arm Description

Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.

Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.

3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.

3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.

Outcomes

Primary Outcome Measures

Change in tracking test performance
The total time outside the road will be measured in the tracking test

Secondary Outcome Measures

Change in simple reaction time (SRT)
Test will be performed using the computerized cognitive testing battery CANTAB and mean latency will be measured
Change in movement estimation
The lapse of time between actual and predicted time will be measured in a movement estimation task
Change in memory function
The N-Back test will be performed with 2 different options: 0 back test and 2 back test
Change in drunkenness
Drunkenness will be measured using a visual analog scale (0-100 mm)
Change in drowsiness
Drowsiness will be measured using a visual analog scale (0-100 mm)
Change in headache
Headache will be measured using a visual analog scale (0-100 mm)
Change in palpitations
Palpitations will be measured using a visual analog scale (0-100 mm)
Change in anxiety
Anxiety will be measured using a visual analog scale (0-100 mm)
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Subjective effects of alcohol and caffeine will be measured using Addiction Research Center Inventory
Change in subjective effects measured with Biphasic alcohol effects scale (BAES)
Subjective effects of alcohol will be measured using BAES
Change in blood pressure
Systolic and diastolic blood pressure will be measured
Change in heart rate
Heart rate will be measured
Change in oral temperature
Oral temperature will be measured
Number of participants with serious and non-serious adverse events
Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators
Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations
Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50h , 0.75, 1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration
Area under the concentration-time curve (AUC 0-8h) of taurine blood concentrations
Calculation of AUC of ethanol concentrations obtained baseline and 0.50,1, 1.50, 2, 4, 6 and 8h after administration
Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations
Calculation of AUC of ethanol concentrations obtained baseline and 0,25, 0.50,1, 1.50, 2, 3, 4, 6 and 8h after administration
Area under the concentration-time curve (AUC 0-8h) of ethanol breath air concentrations
Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50, 0.75,1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration
Maximum concentration (Cmax) of taurine
Maximum concentration (Cmax) of ethanol
Maximum concentration (Cmax) of caffeine
Time to reach maximum concentration (tmax) of ethanol
Time to reach maximum concentration (tmax) of caffeine
Time to reach maximum concentration (tmax) of taurine
Blood coagulation prothrombin
Prothrombin time (PT) and ratio will be measured
Blood coagulation thromboplastin
Activated partial thromboplastin time (APTT) and ratio will be measured
Platelet aggregation (function)
Platelet function (PFA) will be measured
Platelet count
Platelet count will be measured
Change in willingness to drive
Willingness to drive in 3 different situations will be measured by means of a visual analog scale
Like the drug (drink)
Drug liking will be measured using a visual analog scale (0-100 mm)

Full Information

First Posted
May 10, 2016
Last Updated
October 18, 2016
Sponsor
Parc de Salut Mar
search

1. Study Identification

Unique Protocol Identification Number
NCT02771587
Brief Title
Interaction of Alcohol With Energy Drinks
Acronym
AEDED
Official Title
Effects of Alcohol and Energy Drinks on Driving Performance and Bleeding Risk
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
June 2016 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parc de Salut Mar

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of the project is to assess whether there is an interaction between the effects of ethanol and energy drinks on driving performance. Secondary objectives include: to evaluate subjective effects (drunkenness) after administration of alcohol and energy drinks, to assess pharmacokinetics of alcohol, caffeine and taurine after alcohol and energy drinks administration and to assess if there is an increased risk of bleeding when both drinks are taken together.
Detailed Description
Consumption of energy drinks improve psychomotor performance and alertness. These drinks contain mostly caffeine, taurine and vitamins. Its consumption associated with ethanol may reduce feelings of drunkenness as the stimulant effects of caffeine could counteract the depressing effects of ethanol on the central nervous system. Reducing the perception of intoxication may predispose the intoxicated person to engage in risky behaviors such as driving under the influence of ethanol and therefore can increase the risk of a traffic accident. Furthermore, the combination of both beverages may increase the risk of bleeding in case of injury as anticoagulant effects have been described for ethanol while antiplatelet effects have been described for caffeine and taurine. A randomized clinical trial will be performed in healthy volunteers administering 4 treatment conditions: alcohol+energy drink, alcohol+placebo of energy drink, placebo of alcohol+energy drink and placebo of alcohol+placebo of energy drink. A multiple dose will be administered separated by 1 hour.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol-Related Disorders, Drinking and Driving
Keywords
alcohol, energy drink, coagulability, caffeine, taurine, driving performance

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Alcohol and energy drink
Arm Type
Experimental
Arm Description
Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
Arm Title
Alcohol
Arm Type
Active Comparator
Arm Description
Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
Arm Title
Energy drink
Arm Type
Active Comparator
Arm Description
3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol and energy drink
Intervention Description
Multiple oral dose of alcohol Multiple oral dose of energy drink
Intervention Type
Dietary Supplement
Intervention Name(s)
Alcohol
Intervention Description
Multiple oral dose of alcohol
Intervention Type
Dietary Supplement
Intervention Name(s)
Energy drink
Intervention Description
Multiple oral dose of energy drink
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
Non-active treatment
Intervention Description
Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
Primary Outcome Measure Information:
Title
Change in tracking test performance
Description
The total time outside the road will be measured in the tracking test
Time Frame
From baseline till 4 hours after administration
Secondary Outcome Measure Information:
Title
Change in simple reaction time (SRT)
Description
Test will be performed using the computerized cognitive testing battery CANTAB and mean latency will be measured
Time Frame
From baseline till 4 hours after administration
Title
Change in movement estimation
Description
The lapse of time between actual and predicted time will be measured in a movement estimation task
Time Frame
From baseline till 4 hours after administration
Title
Change in memory function
Description
The N-Back test will be performed with 2 different options: 0 back test and 2 back test
Time Frame
From baseline till 4 hours after administration
Title
Change in drunkenness
Description
Drunkenness will be measured using a visual analog scale (0-100 mm)
Time Frame
From baseline till 8 hours after administration
Title
Change in drowsiness
Description
Drowsiness will be measured using a visual analog scale (0-100 mm)
Time Frame
From baseline till 8 hours after administration
Title
Change in headache
Description
Headache will be measured using a visual analog scale (0-100 mm)
Time Frame
From baseline till 8 hours after administration
Title
Change in palpitations
Description
Palpitations will be measured using a visual analog scale (0-100 mm)
Time Frame
From baseline till 8 hours after administration
Title
Change in anxiety
Description
Anxiety will be measured using a visual analog scale (0-100 mm)
Time Frame
From baseline till 8 hours after administration
Title
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Description
Subjective effects of alcohol and caffeine will be measured using Addiction Research Center Inventory
Time Frame
From baseline till 8 hours after administration
Title
Change in subjective effects measured with Biphasic alcohol effects scale (BAES)
Description
Subjective effects of alcohol will be measured using BAES
Time Frame
From baseline till 8 hours after administration
Title
Change in blood pressure
Description
Systolic and diastolic blood pressure will be measured
Time Frame
From baseline till 8 hours after administration
Title
Change in heart rate
Description
Heart rate will be measured
Time Frame
From baseline till 8 hours after administration
Title
Change in oral temperature
Description
Oral temperature will be measured
Time Frame
From baseline till 8 hours after administration
Title
Number of participants with serious and non-serious adverse events
Description
Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators
Time Frame
From inclusion till one week after the last experimental session
Title
Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations
Description
Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50h , 0.75, 1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration
Time Frame
From baseline till 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of taurine blood concentrations
Description
Calculation of AUC of ethanol concentrations obtained baseline and 0.50,1, 1.50, 2, 4, 6 and 8h after administration
Time Frame
From baseline till 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations
Description
Calculation of AUC of ethanol concentrations obtained baseline and 0,25, 0.50,1, 1.50, 2, 3, 4, 6 and 8h after administration
Time Frame
From baseline till 8 hours after administration
Title
Area under the concentration-time curve (AUC 0-8h) of ethanol breath air concentrations
Description
Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50, 0.75,1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration
Time Frame
From baseline till 8 hours after administration
Title
Maximum concentration (Cmax) of taurine
Time Frame
From baseline till 8 hours after administration
Title
Maximum concentration (Cmax) of ethanol
Time Frame
From baseline till 8 hours after administration
Title
Maximum concentration (Cmax) of caffeine
Time Frame
From baseline till 8 hours after administration
Title
Time to reach maximum concentration (tmax) of ethanol
Time Frame
From baseline till 8 hours after administration
Title
Time to reach maximum concentration (tmax) of caffeine
Time Frame
From baseline till 8 hours after administration
Title
Time to reach maximum concentration (tmax) of taurine
Time Frame
From baseline till 8 hours after administration
Title
Blood coagulation prothrombin
Description
Prothrombin time (PT) and ratio will be measured
Time Frame
From baseline till 2 hours after administration
Title
Blood coagulation thromboplastin
Description
Activated partial thromboplastin time (APTT) and ratio will be measured
Time Frame
From baseline till 2 hours after administration
Title
Platelet aggregation (function)
Description
Platelet function (PFA) will be measured
Time Frame
From baseline till 2 hours after administration
Title
Platelet count
Description
Platelet count will be measured
Time Frame
From baseline till 2 hours after administration
Title
Change in willingness to drive
Description
Willingness to drive in 3 different situations will be measured by means of a visual analog scale
Time Frame
From baseline till 6 hours after administration
Title
Like the drug (drink)
Description
Drug liking will be measured using a visual analog scale (0-100 mm)
Time Frame
At the end of each experimental session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Understand and accept the study's procedures and sign an informed consent form No evidence of somatic or psychiatric disorders as per past medical history and physical examination EKG, blood and urine tests taken before entry into the study within the normal range. Minor and transient abnormalities may be acceptable if, according to the Principal Investigator's criterion and the state of the art, they are felt to have no clinical relevance, entail no danger to the participant, and don't interfere with the product's assessment. These abnormalities and their non-relevance must be specifically justified in writing) Body mass index (BMI=weight/heigth2) between 19 and 27 kg/m2, weight between 50 and 100 kg For premenopausal females, a regular menstrual cycle of 26-32 days duration. Social or recreational alcohol consumption of at least 1 unit per day (or its equivalent [7 units] over the whole week) and having experienced drunkenness several times Regular consumption of beverages containing methylxanthines (at least 5 per week) Consumption of energy drinks several times previously Having a driving license Exclusion Criteria: Evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of the drug or symptoms suggestive of drug-induced gastrointestinal irritation Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session Smokers of >5 cigarettes/day Consumption of >20 g/day of alcohol (females) or of >40 g/day (males) Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals Pregnant or lactating women, or those using hormonal or unreliable contraceptive methods during the study period. Complete abstinence, intrauterine devices, double barrier methods or a vasectomized sexual partner will be considered acceptable Women with amenorrhea or suffering severe premenstrual syndrome Individuals of Asian ascent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clara Pérez Mañá, PhD, MD
Organizational Affiliation
IMIM
Official's Role
Principal Investigator
Facility Information:
Facility Name
IMIM
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Parc de Salut Mar-IMIM
City
Barcelona
ZIP/Postal Code
08003
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34338762
Citation
Perez-Mana C, Mateus JA, Diaz-Pellicer P, Diaz-Baggerman A, Perez M, Pujadas M, Fonseca F, Papaseit E, Pujol J, Langohr K, de la Torre R. Effects of Mixing Energy Drinks With Alcohol on Driving-Related Skills. Int J Neuropsychopharmacol. 2022 Jan 12;25(1):13-25. doi: 10.1093/ijnp/pyab051.
Results Reference
derived

Learn more about this trial

Interaction of Alcohol With Energy Drinks

We'll reach out to this number within 24 hrs